Humira: strong results against Crohn's disease

Patients with moderate-to-severely active Crohn's disease treated with Humira (adalimumab) saw continuing improvements in clinical response and clinical remission, according to recent Phase III study data from the USA's Abbott Laboratories.

After 24 weeks, 78% of subjects who completed open-label treatment saw improvement in their disease, as measured by a decrease of more than 70 points from baseline in their Crohn's Disease Activity Index. Of the 220 patients involved, 33% achieved clinical remission, defined as a CDAI of less than 150, the firm added.